Clinical trials: Glial Tumors
Brain and Central Nervous System Tumors
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
RATIONALE: Radioactive drugs such as phosphorus 32 may be able to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of phosphorus 32 in treating patients with glioblastoma multiforme.
- Trial name
- NCT00004129
- Testing
- brachytherapy, phosphorus P32
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Center for Molecular Medicine
Brain Tumor, Brain Tumor, Recurrent
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Brain Cancer
- Trial name
- NCT00747253
- Testing
- AutoLITT system
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Monteris Medical
Glioma, Malignant, New Diagnosis Tumor
Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma
The goal of this clinical trial is to learn about the safety and feasibility of administering repeated doses of neural stem cell (NSC)-conditionally replicative adenovirus (CRAd)-survivin (S)-protomer (p)k7, in persons with newly…
- Trial name
- NCT06169280
- Testing
- NSC-CRAd-S-pk7
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Glioblastoma, Glioma
Memory Perception Assessment in Central/Non-central Nervous System Cancers
Prospective memory (PM) is the ability to implement intended actions in the future. It allows maintaining and retrieving future plans, goals, and activities (i.e., remember to remember).
- Conditions
- Glioblastoma, Glioma, Breast Cancer, Healthy
- Trial name
- PROMESSE (NCT03975959)
- Testing
- QMRP questionnaire
- Where
- 6 sites in France
- Volunteers
- 426 people, healthy volunteers welcome
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Cilengitide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00085254
- Testing
- cilengitide, temozolomide, radiation therapy
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Small Cell Glioblastoma
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express…
- Conditions
- Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- ACT IV (NCT01480479)
- Testing
- Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH
- Where
- 223 sites in United States, Australia and 22 more
- Volunteers
- 745 people
- Sponsor
- Celldex Therapeutics
Newly Diagnosed High-Grade Glioma
Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide
The purpose of this study is to find the highest dose of mebendazole (MBZ) that can be safely given to people with malignant brain tumors in combination with the current standard of care (temozolomide) without causing severe side…
- Trial name
- Mebendazole (NCT01729260)
- Testing
- Mebendazole
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme
Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme
Local recurrence is a major problem of clinical treatment of glioblastoma multiforme (GBM). Today a very sensitive imaging method to detect glioblastoma is [11C]MET Positron emission tomography (PET), where in some patients also…
- Trial name
- NCT01873469
- Testing
- Radiochemotherapy
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- Technische Universität Dresden
Brain and Central Nervous System Tumors
Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. External-beam radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00053183
- Testing
- conventional surgery, brachytherapy, radiation therapy
- Where
- 10 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Ependymoma
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide were allowed to participate in…
- Trial name
- NCT01247922
- Testing
- Erlotinib
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 4 people
- Sponsor
- OSI Pharmaceuticals
Glioblastoma, Malignant Gliomas
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas
- Trial name
- NCT00074646
- Testing
- CC-8490
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Celgene Corporation
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00004146
- Testing
- radiation therapy, carboxyamidotriazole, pharmacological study
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Glioma
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.
Gimatecan® is Sigma-Tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors.
- Trial name
- NCT00032903
- Testing
- Gimatecan® (ST 1481)
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sigma-Tau Research, Inc.
Advanced Malignancies That Harbor IDHR132 Mutations
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
- Trial name
- NCT02381886
- Testing
- IDH305
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with SC-CAR4BRAIN, an autologous CD4+ and CD8+ T cells lentivirally transduced to express to express combinations of B7-H3, EGFR806, HER2, and…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult, Recurrent, CNS Tumor, Childhood
- Trial name
- NCT05768880
- Testing
- SC-CAR4BRAIN
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Seattle Children's Hospital
Brain Tumors
Fluorescence Guided Resection of Brain Tumors
Removing a tumor from your brain is hard to do because, very often, brain tumors do not have boundaries that are easy for your surgeon to find. In many cases, the surgeon can't tell exactly where the tumor begins or ends.
- Trial name
- FGR (NCT00870779)
- Testing
- 5-aminolevulinic acid
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- David W. Roberts
Diffuse Glioma, Glioblastoma
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics.
- Conditions
- Diffuse Glioma, Glioblastoma, Adaptive Radiotherapy, Artificial Intelligence
- Trial name
- GLADIATOR (NCT06492486)
- Testing
- Adaptive radiotherapy
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Centre
Pediatric Central Nervous System Tumors, Medulloblastoma
Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors
his is a single-center, prospective observational study in children and adolescents with central nervous system tumors who need whole-brain and whole-spine radiation therapy (craniospinal irradiation, CSI).
- Conditions
- Pediatric Central Nervous System Tumors, Medulloblastoma, Germinoma, Ependymoma
- Trial name
- VBS-CSI-PT-PED (NCT07589361)
- Testing
- Vertebral Body-Sparing Craniospinal Proton Irradiation
- Volunteers
- 38 people
- Sponsor
- Ruijin Hospital
High-grade Gliomas (HGG)
Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas
The purpose of this study is to learn whether two alternatives to standard steroid treatment can safely control swelling around a brain tumor after surgery.
- Trial name
- NCT07694089
- Testing
- Dexamethasone, Azeliragon
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Akshitkumar MIstry
Patients With Residual or Reccurent EGFRvIII+ Glioma
Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
An Open-Label Phase 1 Pilot Study to determine the safety and feasibility of CART-EGFRvIII (autologous T cells transduced with a lentiviral vector to express a chimeric antigen receptor specific for EGFRvIII) in the treatment of…
- Trial name
- NCT02209376
- Testing
- CART-EGFRvIII T cells
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Pennsylvania
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.